SITE001-0099

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE001 (USA) (Dr. Reyes) · consented 2022-06-20

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

severe assessed 2026-08-18

Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-08-30 (study day 57); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 177); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-04 (study day 427); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-09-16 (study day 439); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-11-03 (study day 487); relationship: N

severe serious assessed 2026-08-18

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-11-24 (study day 508); relationship: not assessed; serious criteria: hospitalization

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.